Bremer Trust National Association’s Alexion Pharmaceuticals ALXN Stock Holding History

Bremer Trust National Association’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1.76M	Buy	18,045 +1,346	+8%	+$159K	0.38%	71
2018 Q3	$2.32M	Buy	16,699 +3,678	+28%	+$461K	0.58%	40
2018 Q2	$1.62M	Buy	13,021 +9,792	+303%	+$1.14M	0.45%	58
2018 Q1	$360K	Sell	3,229 -939	-23%	-$112K	0.1%	168
2017 Q4	$498K	Buy	4,168 +69	+2%	+$8.4K	0.13%	147
2017 Q3	$575K	Sell	4,099 -260	-6%	-$35.3K	0.16%	133
2017 Q2	$531K	Sell	4,359 -1,125	-21%	-$131K	0.15%	138
2017 Q1	$665K	Buy	5,484 +94	+2%	+$12.1K	0.18%	124
2016 Q4	$660K	Sell	5,390 -88	-2%	-$10.8K	0.18%	134
2016 Q3	$672K	Buy	5,478 +26	+0.5%	+$3.35K	0.18%	132
2016 Q2	$637K	Sell	5,452 -118	-2%	-$16.7K	0.18%	118
2016 Q1	$776K	Buy	5,570 +148	+3%	+$21.7K	0.22%	105
2015 Q4	$1.03M	Sell	5,422 -226	-4%	-$39.5K	0.31%	85
2015 Q3	$883K	Sell	5,648 -1,010	-15%	-$184K	0.29%	89
2015 Q2	$1.2M	Buy	6,658 +4	+0.1%	+$690	0.36%	73
2015 Q1	$1.15M	Buy	6,654 +579	+10%	+$105K	0.37%	73
2014 Q4	$1.12M	Buy	6,075 +599	+11%	+$111K	0.36%	70
2014 Q3	$908K	Buy	5,476 +3	+0.1%	+$493	0.31%	81
2014 Q2	$855K	Sell	5,473 -701	-11%	-$111K	0.3%	82
2014 Q1	$940K	Sell	6,174 -315	-5%	-$50.1K	0.35%	68
2013 Q4	$863K	Sell	6,489 -232	-3%	-$27.8K	0.33%	69
2013 Q3	$781K	Buy	6,721 +9	+0.1%	+$987	0.33%	73
2013 Q2	$619K	Buy	+6,712	New	+$647K	0.28%	83

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bremer Trust National Association's ALXN Position: Q4 2018 in Review

Bremer Trust National Association increased its Alexion Pharmaceuticals (ALXN) stake by 8.1% in Q4 2018, buying an estimated $159K and bringing the position to 18,045 shares worth $1.76M. The position accounts for 0.38% of the portfolio, ranked #71.

Bremer Trust National Association first reported a position in ALXN in Q2 2013 and has held it in 23 quarters since. The position peaked at $2.32M in Q3 2018. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Bremer Trust National Association held 18,045 shares of Alexion Pharmaceuticals worth $1.76M as of Q4 2018.
Bremer Trust National Association bought 1,346 Alexion Pharmaceuticals shares in Q4 2018, an estimated $159K.
Alexion Pharmaceuticals made up 0.38% of Bremer Trust National Association's portfolio in Q4 2018, its #71 holding.
Bremer Trust National Association first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 23 quarters since.
Bremer Trust National Association's Alexion Pharmaceuticals position peaked at $2.32M in Q3 2018.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Bremer Trust National Association's 13F filing for Q4 2018, filed 11 Feb 2019.